uniQure N.V. (QURE) stock
QURENasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30224% above fair value
$20.78−1.10 (-5.03%)
Close on Nov 17, 2026Market cap $1.44BP/E –Yield –
uniQure ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
uniQure's ebitda for the twelve months ending Jun 30, 2026 was -$185.61M. For fiscal 2025 it was -$170.59M. The highest annual figure on record is $317.92M in fiscal 2021.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$170.59M | – |
| FY2024 | Dec 31, 2024 | -$171.65M | – |
| FY2023 | Dec 31, 2023 | -$270.97M | – |
| FY2022 | Dec 31, 2022 | -$134.62M | -142.3% |
| FY2021 | Dec 31, 2021 | $317.92M | – |
| FY2020 | Dec 31, 2020 | -$114.78M | – |
| FY2019 | Dec 31, 2019 | -$114.47M | – |
| FY2018 | Dec 31, 2018 | -$75.82M | – |
| FY2017 | Dec 31, 2017 | -$63.80M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$47.30M | – |
| Q1 FY2026 | Mar 31, 2026 | -$42.76M | – |
| Q4 FY2025 | Dec 31, 2025 | -$48.15M | – |
| Q3 FY2025 | Sep 30, 2025 | -$47.40M | – |
| Q2 FY2025 | Jun 30, 2025 | -$40.24M | – |
| Q1 FY2025 | Mar 31, 2025 | -$34.80M | – |
| Q4 FY2024 | Dec 31, 2024 | -$41.47M | – |
| Q3 FY2024 | Sep 30, 2024 | -$37.24M | – |
| Q2 FY2024 | Jun 30, 2024 | -$41.34M | – |
| Q1 FY2024 | Mar 31, 2024 | -$51.60M | – |
| Q4 FY2023 | Dec 31, 2023 | -$57.56M | -299.6% |
| Q3 FY2023 | Sep 30, 2023 | -$79.28M | – |
| Q2 FY2023 | Jun 30, 2023 | -$62.49M | – |
| Q1 FY2023 | Mar 31, 2023 | -$71.65M | – |
| Q4 FY2022 | Dec 31, 2022 | $28.83M | +635.5% |
| Q3 FY2022 | Sep 30, 2022 | -$57.42M | – |
| Q2 FY2022 | Jun 30, 2022 | -$54.08M | -113.5% |
| Q1 FY2022 | Mar 31, 2022 | -$51.96M | – |
| Q4 FY2021 | Dec 31, 2021 | $3.92M | – |
| Q3 FY2021 | Sep 30, 2021 | -$43.22M | – |
| Q2 FY2021 | Jun 30, 2021 | $399.81M | – |
| Q1 FY2021 | Mar 31, 2021 | -$42.60M | – |
| Q4 FY2020 | Dec 31, 2020 | -$5.97M | – |
| Q3 FY2020 | Sep 30, 2020 | -$39.64M | – |
| Q2 FY2020 | Jun 30, 2020 | -$36.44M | – |
| Q1 FY2020 | Mar 31, 2020 | -$32.73M | – |
| Q4 FY2019 | Dec 31, 2019 | -$31.24M | – |
| Q3 FY2019 | Sep 30, 2019 | -$29.61M | – |
| Q2 FY2019 | Jun 30, 2019 | -$27.68M | – |
| Q1 FY2019 | Mar 31, 2019 | -$25.94M | – |
| Q4 FY2018 | Dec 31, 2018 | -$22.24M | – |
| Q3 FY2018 | Sep 30, 2018 | -$15.99M | – |
| Q2 FY2018 | Jun 30, 2018 | -$19.54M | – |
| Q1 FY2018 | Mar 31, 2018 | -$18.05M | – |
| Q2 FY2017 | Jun 30, 2017 | -$17.25M | – |
| Q1 FY2017 | Mar 31, 2017 | -$17.92M | – |
See a number that looks wrong?